Mark Burkard, MD
Medical Oncology · Iowa City, IANPI 1194903971
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,655 of the $10,389 with a category attached, or 73.7%. Novartis accounts for 85.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $6,348 and has fallen 93.6% since, to $404 in 2024.
Across 19 payments — averaging $546.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- Athenex Pharmaceutical Division, LLC$625
- AstraZeneca$496
- Puma Biotechnology, Inc.$192
- F. Hoffmann-la Roche AG$100
- Macrogenics, Inc.$96
- plus $12 from 1 others
Across 188 payments — averaging $14,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.4M
- Seagen Inc.$451K
- Puma Biotechnology, Inc.$300K
- AstraZeneca$212K
- Novartis$118K
- Pfizer$111K
- plus $187K from 4 others
What the payments were for
- Consulting fees$7,65574%
- Speaking & faculty fees$6256%
- Grants$3503%
- Travel & lodging$9289%
- Food & beverage$8198%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $8,869 |
| Athenex Pharmaceutical Division, LLC | 1 | $625 |
| AstraZeneca | 3 | $496 |
| Puma Biotechnology, Inc. | 4 | $192 |
| F. Hoffmann-la Roche AG | 1 | $100 |
| Macrogenics, Inc. | 1 | $96 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PIQRAY$5,660
- Oral Paclitaxel$625
- Encequidar$625
- Non-Covered Product$100
How this compares
$10,389 in reported general payments places this provider in the 85th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 27 | $422,654 |
| Anastrozole | 284 | $5,125 |
| Exemestane | 21 | $2,756 |
| Tamoxifen Citrate | 94 | $2,339 |
| Letrozole | 80 | $887 |
| Dexamethasone | 12 | $700 |
| Gabapentin | 18 | $288 |
| Alendronate Sodium | 32 | $167 |
| Ondansetron Hcl | 16 | $137 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Iowa City
- Jun ZhangIowa City$377K
- John RiethIowa City$11K
- Fernando Maciel BarbosaIowa City$3K
- Gustavo Fernandes Godoy AlmeidaIowa City$2K
- Margaret ByrneIowa City$1K
- Naomi FeiIowa City$1K
- Saima SharifIowa City$122
- Susan RoederIowa City$47
- Margarida SilvermanIowa City$0
- Tara GraffClive$702K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.